Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Inclusion Criteria: * Adult patients, 18 years or older * Diagnosed Pachyonychia Congenita (PC), genetically confirmed * Moderate to Severe PC * Able and willing to comply with all protocol-required activities * Willing and able to provide written informed consent Exclusion Criteria: * Any significant concurrent condition (including involving the inferior to the ankle) that could adversely affect participation. * Any intentional changes in the patient's daily activities (associated with standing, walking and keeping balance), not resulting from an improvement in the patient's condition due to treatment. * Patient's deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities.